Increased heart rate and left ventricular pressure during humoral and neuronal adrenergic activation act to restrict blood flow preferentially in the subendocardium. The hypothesis was advanced that a-adrenergic coronary vasoconstriction preferentially in the subepicardium may counterbalance the enhanced extravascular compression in the subendocardium and serve to maintain blood flow transmurally uniform. In 40 anesthetized dogs, regional myocardial blood flow was determined with colored microspheres; wall function, with sonomicrometry. Humoral adrenergic activation (HAA) was induced by a combination of intravenous atropine, intravenous norepinephrine, and atrial pacing during baseline coronary vasomotor tone (group 1, n=6) and in the presence of maximal coronary vasodilation with intravenous dipyridamole (group 2, n=6). In an additional group, HAA was induced by intravenous norepinephrine in the presence of dipyridamole but without atropine and atrial pacing in order to increase end-diastolic left ventricular pressure (group 3, n=6). Measurements were performed at rest, during HAA, and during ongoing HAA with the intracoronary infusion of the a-antagonist phentolamine (Phen). At unchanged mean aortic pressure, Phen improved blood flow particularly to the inner layers as follows: from 1.42±0.40 (mean+SD) to 1.90±0.40 mL/(min g) (group 1, P<.05), from 4.99+2.31 to 5.53±2.56 mL/(min g) (group 2, P<.05), and from 6.01±1.41 to 6.29±1.27 mL/(ming) (group 3, P<.05), associated with a decrease in outer layer blood flow in groups 2 and 3. In 16 additional dogs, 13-adrenoceptors were blocked by propranolol and muscarinic receptors by atropine. Neuronal adrenergic activation (NAA) was induced by cardiac sympathetic nerve stimulation (CSNS) during baseline coronary vasomotor tone (group 4, n=8) and in the presence of maximal vasodilation (group 5, n=8). Measurements were performed at rest, during a first CSNS, and 20 minutes later during a second CSNS+Phen. The reproducibility of two consecutive episodes of CSNS 20 minutes apart was demonstrated in a separate set of experiments (n=6). At matched mean aortic pressures, Phen improved blood flow to all myocardial layers in group 4, whereas in group 5, Phen induced a redistribution of myocardial blood flow toward subepicardial layers [from 4.44±0.96 to 4.81±0.83 mL/(min * g), P<.051 at the expense of inner layers.
excitement, pain, and sympathetic reflex activation acts to enhance the level of circulating catecholamines as well as the activity of cardiac sympathetic nerves. The activation of cardiac 8-adrenoceptors by humoral and neuronal catecholamines mediates an increase in heart rate (HR) and myocardial inotropic state, thereby increasing both myocardial oxygen consumption (MVo2)1 and extravascular compression.2 Extravascular compression acts to restrict blood flow preferentially in the subendocardium. [3] [4] [5] The increased oxygen demand is adequately matched by an augmented oxygen supply after metabolic vasodilation of the coronary vasculature under normal conditions.1 The direct effect of norepinephrine on the coronary smooth muscle cells is vasoconstriction through activation of both aland a2-adrenoceptors.6-9 Thus, a-adrenergic coronary vasoconstriction competes with metabolic vasodilation,101 although the net effect of humoral and neuronal adrenergic activation under physiological condi-tions is always an increase in coronary blood flow. Nevertheless, a-adrenergic coronary vasoconstriction during intracoronary norepinephrine infusion, reflex sympathetic activation, and exercise attenuates the increase in coronary blood flow by approximately 20% to 30%."",12 Such an attenuation of the increase in coronary blood flow, when oxygen demand is augmented, seems paradoxical. 13 The question of whether'3 or not14 there is still a physiological role for a-adrenergic coronary vasoconstriction remains.
From a teleological point of view, the hypothesis that a-adrenergic coronary vasoconstriction is operative preferentially in the subepicardium and may counterbalance the enhanced extravascular compression in the subendocardium appears to be reasonable. Thus, a-adrenergic coronary vasoconstriction may help to maintain uniform blood flow across the left ventricular wall during intense adrenergic activation. This hypothesis was initially proposed by Johannsen et al,15 who confirmed previous experiments by Giudicelli et al16 showing that cardiac sympathetic nerve stimulation in the presence of l3-adrenoceptor blockade reduced blood flow more in the subepicardial than in the subendocardial layers.
In the experiments by Giudicelli et al16 and Johannsen et al, 15 cardiac sympathetic nerve stimulation improved the ratio of subendocardial to subepicardial blood flow. However, this improved blood flow ratio was nevertheless associated with a decrease in absolute subendocardial blood flow. Since such an improved blood flow ratio was observed only during cardiac sympathetic nerve stimulation but not in response to intracoronary norepinephrine, the nonuniform constrictor response was assumed to reflect a more pronounced inhibitory action of adenosine on sympathetic neurotransmission in the inner myocardial layers. 15 Feigl and Huang"3,17 extended the hypothesis of a favorable effect of a-adrenergic coronary vasoconstriction on transmural blood flow distribution from neuronal to humoral norepinephrine, because the coronary vasomotor responses during dynamic exercise are predominantly exerted by circulating catecholamines. 18 In their experiments, during dynamic exercise in dogs, the ratio of subendocardial to subepicardial blood flow in an unblocked anterior control region was better than in a posterior region of the left ventricle that was a-adrenergically blocked with phenoxybenzamine.17 However, no separate data for subendocardial and subepicardial blood flow in the a-adrenergically blocked and in the intact region were presented, and an increase in inner to outer flow ratio does not necessarily imply an increase in subendocardial blood flow.'156'9 It is also unclear whether phenoxybenzamine, which predominantly blocks a,-adrenoceptors20 in the present study and in the study by Giudicelli et al, 16 completely blocked a2-adrenoceptors.
Feigl'3 also somewhat modified the original hypothesis proposed by Giudicelli et al16 and Johannsen et al'5 that a-adrenergic coronary vasoconstriction during cardiac sympathetic nerve stimulation predominantly affects the subepicardium and, thus, counteracts the enhanced extravascular compression that primarily affects the subendocardium. Feigl proposed that a-adrenergic coronary vasoconstriction stiffens vessels and, facilitates their reexpansion during diastole, thereby permitting increased diastolic flow particularly to subendocardial layers when diastolic duration is reduced at high rates. 7 Although this is an interesting idea concerning the effect of a-adrenergic coronary vasoconstriction on transmural blood flow distribution, there are currently no data to support it.
In the absence of 3-adrenoceptor blockade, presynaptic a1-and a,-adrenoceptor blockade during exer-cise2122 or cardiac sympathetic nerve stimulation'2324 results in an augmentation of norepinephrine release from nerve terminals, which in turn improves global ventricular212225-27 and regional myocardial wall222627 function. In contrast, no augmentation of global ventricular and regional myocardial wall function was observed after selective a1-and a2-adrenoceptor blockade during exercise in the presence of p-adrenoceptor blockade. 22 With consideration of the above-mentioned limitations of the previous studies on this topic, the present study critically tested the hypothesis that a-adrenergic coronary vasoconstriction exerts a favorable effect on the transmural myocardial blood flow distribution during humoral and neuronal adrenergic activation and attenuates the undesirable extravascular effects of an increased HR3 and an increased end-diastolic left ventricular pressure (LVP)4 on the transmural blood flow distribution. Humoral adrenergic activation was induced by intravenous infusion of norepinephrine and neuronal adrenergic activation by cardiac sympathetic nerve stimulation in open-chest mongrel dogs. To adequately test the hypothesis, the study design also required the creation of a flow-limited situation by maximal coronary vasodilation and the exclusion of effects secondary to presynaptic a-adrenoceptor blockade during cardiac sympathetic nerve stimulation by sufficient 13-adrenoceptor blockade.
Materials and Methods
The dogs were handled according to the guidelines of the American Physiological Society, and the protocol was approved by the bioethical committee of the district of Dusseldorf, Germany.
Experimental Preparation
Forty mongrel dogs (25 to 39 kg body weight) were anesthetized with sodium thiamylal (20 mg/kg IV). After endotracheal intubation, anesthesia was maintained by ventilation with a nitrous oxide and oxygen mixture (70%:30%) using a respirator (Spiromat 650, Drager Werke AG, Liibeck, Germany) and by the infusion of piritramide (40 to 60 mg/h IV). Arterial blood gases and hematocrit were monitored periodically (BMS 3 MK 2 Blood Micro System, Radiometer, Copenhagen, Denmark) and maintained within the normal range.28 Rectal temperature was monitored and maintained above 37°C using a heating pad.
A Teflon catheter (internal diameter, 2.0 mm) was inserted via the right femoral artery into the upper descending aorta for blood withdrawal. A second Teflon catheter was inserted into the right femoral vein for drug infusion and volume replacement. A balloon catheter (Fogarty occlusion catheter 8/22F, Baxter GmbH, UnterschleiBheim, Germany) was inserted through the left femoral artery. The balloon was placed in the thus, both reduces their compression during systole and descending aorta approximately 10 cm distal to the Baumgart et al cr-Adrenergic Coronary Constriction and Myocardial Blood Flow Distribution 871 ostium of the withdrawal catheter. Controlled inflation of the balloon served to compensate for decreases in mean aortic pressure (AOP) following a-adrenoceptor blockade.
A left thoracotomy was performed in the fifth intercostal space. The pericardium was opened and sutured to cradle the heart. A micromanometer (model P7, Konigsberg, Pasadena, Calif) was inserted through the apex to measure LVP. The micromanometer was calibrated by measurement of the LVP through a fluidfilled catheter; zero pressure reference was taken at the level of the right atrium. HR and the first derivative of LVP (LV dP/dt) were derived from the LVP signal. Proximal AOP was measured with a catheter-tipped manometer (model PC 350, Millar Instruments, Houston, Tex) inserted via the right brachial artery into the aortic root. A Teflon catheter (internal diameter, 2 mm) was placed into the left atrium through the atrial appendage for microsphere injections. Two electrode wires were sutured to the left atrial appendage for pacing with a stimulator (type 215/I, Hugo Sachs Elektronik, March-Hugstetten, Germany). A SF Gooddale-Lubin catheter (USCI, C.R. Bard Ireland Limited, Galway, Ireland) was advanced from the right jugular vein into the coronary sinus with the catheter tip 2 cm upstream from the ostium. This catheter was used to sample coronary venous blood. Oxygen content was determined in blood samples from the left femoral artery and the coronary sinus (Lex-02-Con, Lexington Instruments, Lexington, Ky). Ultrasonic crystals were implanted in the anterior left ventricular wall (control region) perfused by the left anterior descending coronary artery (LAD) and in the posterolateral wall (region of interest) perfused by the left circumflex coronary artery (LCX) for measurement of regional myocardial wall thickness using standard techniques29 (Sonomicrometer 120, Triton Technologies Inc, San Diego, Calif). In 22 of the dogs studied (groups 3, 4, and 5), additional ultrasonic crystals were implanted in the LCX-perfused myocardium to measure subendocardial and subepicardial segment lengths. The LCX was dissected free for approximately 1 cm proximal to its first side branch for placement of an electromagnetic flow probe (Spectramed, Statham, Oxnard, Calif) in the 12 dogs of groups 1 and 2. The flow probe was used to monitor changes in coronary blood flow on-line and to determine a steady-state response to intracoronary phentolamine as a prerequisite for regional myocardial blood flow measurements using microspheres and to confirm maximal coronary vasodilation with dipyridamole by lack of reactive hyperemia. To avoid a potential denervation, particularly in dogs undergoing cardiac sympathetic nerve stimulation, the implantation of a flow probe on the LCX was omitted in dogs of groups 3, 4, and 5. To verify maximal coronary vasodilation after dipyridamole by the lack of reactive hyperemia in groups 3 and 5, a flow probe was implanted on the distal LAD. In all dogs, a 27-gauge cannula (Microlance, Becton-Dickenson Limited, Dublin, Ireland) was inserted with minimal epivascular dissection into the LCX for intracoronary infusion of saline or phentolamine. The LCX-perfused region was chosen as the region of interest, since acute coronary dissection may produce sympathetic denervation of the LAD-perfused re-denervation of the posterolateral wall, either with respect to regional myocardial blood flow15 or with respect to myocardial function.31'32 Measurement of Regional Myocardial Blood Flow
Regional myocardial blood flow (RMBF) was determined using a technique developed in our laboratory.33 Microspheres (15 ,um) were dyed with one of five different colors (Dye-Trak, Triton Technologies). For each measurement, approximately 3 x 106 to 21 x 106 microspheres suspended in 6 mL saline (containing 0.02% Tween 80) were injected into the left atrium. The number of microspheres was adjusted with respect to the specific absorbance of the respective dye, ie, 9 x 106 to 10X106 for white, 6x106 to 12x106 for yellow, 3x 106 to 6x 106 for red, 6x 106 to 14x106 for blue, and 9x106 to 21 X 106 for violet microspheres. Each microsphere injection was followed by a flush of 6 mL saline. The withdrawal of arterial reference blood samples was started 30 seconds before injection of the microspheres and continued for 120 seconds at a rate of 5.3 mL/min (withdrawal pump model 901A, Harvard Apparatus, South Natick, Mass).
Study Protocol
After completed instrumentation, systemic hemodynamics, MVo2, RMBF, and regional myocardial function were measured under steady-state conditions at rest. The measurements were repeated during humoral and neuronal adrenergic activation, without and with the addition of phentolamine. In three experimental subgroups of dogs (groups 3, 4, and 5), additional measurements were performed during steady-state conditions immediately before humoral or neuronal adrenergic activation. These were the subgroups of dogs in which additional ultrasonic crystals were implanted to measure posterior subendocardial and subepicardial segment lengths.
Humoral Adrenergic Activation During Baseline Coronary Vasomotor Tone: Effect of a-Blockade (Group 1)
Humoral adrenergic activation was produced by (1) muscarinic blockade using atropine (6 mg IV) to simulate vagal withdrawal and prevent vagal counterregulation, (2) infusion of norepinephrine in a dose sufficient to increase maximum systolic LVP to > 140 mm Hg (2 to 40 ,ug/min IV), and (3) increasing HR to more than 190 beats per minute by left atrial pacing. Saline (1 mL/min) was infused continously via the intracoronary cannula into the LCX. During ongoing humoral adrenergic activation, the saline infusion was stopped, and the a-antagonist phentolamine [10 ,ug/(min kg)] was infused at an identical infusion rate of 1 mL/min. The intracoronary infusion was used to achieve a maximal regional effect of phentolamine and to minimize its systemic effects. Nevertheless, after approximately 2 minutes, a decrease in AOP was detected, indicating the beginning systemic action of phentolamine. By controlled inflation of the intra-aortic balloon, however, mean AOP was matched to the mean AOP before a-adrenoceptor blockade and gion30,31 but does not cause significant sympathetic measurements were performed. After the injection of atropine, the reactive hyperemia following a 15-second occlusion of the LCX was determined. Dipyridamole (0.3 mg/kg) was then administered in a dose sufficient to abolish reactive hyperemia following a second 15-second occlusion of the LCX. The absence of reactive hyperemia was again confirmed at the end of the study. Humoral adrenergic activation was induced as described above, and the study protocol was continued as for group 1.
Humoral Adrenergic Activation Without Atropine and Atrial Pacing During Maximal Coronary
Vasodilation: Effect of a-Blockade (Group 3)
Reactive hyperemia was determined on the LAD before and after the administration of dipyridamole as described above. The absence of reactive hyperemia was again confirmed at the end of the study. In this group of dogs, humoral adrenergic activation was induced by intravenous norepinephrine only, but without atropine and atrial pacing to achieve a longer duration of diastole and an increase in end-diastolic LVP. The study protocol was otherwise performed as for group 2.
Neuronal Adrenergic Activation During Baseline Coronary Vasomotor Tone: Effect of a-Blockade (Group 4)
,1-Adrenoceptors were blocked with propranolol (2 mg/kg IV). The left ventrolateral cervical cardiac nerve34 was identified, isolated approximately halfway between the stellate ganglion and the pericardium, and cut. To induce neuronal adrenergic activation, the distal nerve was then stimulated at 20 Hz with 2-millisecond pulses of 4 to 10 V. Current spread to adjacent nerves was prevented by immersing the stimulation site in liquid paraffin. Since a stable steady-state cardiac sympathetic nerve stimulation cannot be maintained for longer than 2 to 3 minutes and, on the other hand, microsphere measurements require reference withdrawal times of approximately 2 minutes, we performed two consecutive cardiac sympathetic nerve stimulations separated by an interval of 20 minutes. The reproducibility of two series of cardiac sympathetic nerve stimulations with identical stimulation characteristics 20 minutes apart was demonstrated in a separate set of experiments under conditions of maximal vasodilation by dipyridamole (n=6) ( Table 1) . For the study of a-adrenergic coronary vasoconstriction, the first cardiac sympathetic nerve stimulation was then performed, and measurements were taken while saline was infused into the LCX at 1 mL/min. Two minutes before the second cardiac sympathetic nerve stimulation was started 20 minutes later, the saline infusion (1 mL/min) was stopped, and the a-antagonist phentolamine was infused into the LCX in a dosage of 50 ,ug/(min * kg) at an identical infusion rate. By controlled inflation of the intra-aortic balloon, mean AOP was matched to the mean AOP before a-adrenoceptor blockade, and measurements were performed. Measurements including the determination of RMBF were made during steady-state conditions, ie, between 30 and 150 seconds of cardiac sympathetic nerve stimulation. In preliminary experiments, we found that a fivefold higher dose of phentolamine was needed to observe a sizeable and similar increase in transmural blood flow with neuronal as compared with humoral adrenergic activation.
Neuronal Adrenergic Activation During Maximal Coronary Vasodilation: Effect of a-Blockade (Group 5)
Dipyridamole (0.3 mg/kg) was administered in a dose sufficient to abolish reactive hyperemia on the LAD. The absence of reactive hyperemia was confirmed at the end of the study. Neuronal adrenergic activation was induced as described above, and the study protocol was continued as for group 4.
Postmortem Analysis
At the end of each experiment, the perfusion territory of the LCX was delineated by intracoronary injection of methylene blue immediately before euthanatiz- ing the dogs by intracardiac injection of potassium chloride. The perfusion territory of the LCX was cut out and weighed. The myocardial regions containing the ultrasonic crystals in both the anterior and the posterior region were cut out, and the position of the inner crystals was verified. In these two blocks of tissue (approximately 9 g each), RMBF in the subendocardium, midmyocardium, and subepicardium was determined as described previously.33 Each block of myocardial tissue was cut in an array of 3 x 3 transmural blocks with three layers each, resulting in 27 myocardial sam-ples per perfusion territory. The blood flow values in the nine samples per layer were averaged for each individual animal, and this average value was used for the statistical analysis of the effects of phentolamine (Tables 2 through 6 ). After extraction of the dye, the color spectra of each sample were measured by a spectrophotometer (model 8452A, Hewlett-Packard Co, Palo Alto, Calif). Separation of overlapping spectra was performed by use of a matrix inversion technique.35 RMBF per sample, corrected for wet weight, was calculated using the following equation: 
Data Analysis
Systemic hemodynamics and myocardial wall thickness of the anterior and the posterior wall and posterior subendocardial and subepicardial segment lengths were continuously monitored on an eight-channel forced-ink chart recorder (Hellige & Co, GmbH, Freiburg i. Br., Germany) and stored on magnetic tape (Racal Recorders Ltd, Southampton, UK). Data were digitized in 5-millisecond intervals using a software package Values for MVo02 were normalized for 100 g of perfused myocardial tissue.
Statistical Analysis
Data are reported as mean±-fSD. Changes in systemic hemodynamics, regional myocardial dimensions, RMBF, and MVo02 in response to phentolamine were statistically evaluated. Therefore, data during humoral adrenergic activation without and with the addition of phentolamine or cardiac sympathetic nerve stimulation without and with the addition of phentolamine, respectively, were compared by a two-tailed paired t test. A value of P< .05 was taken to indicate a significant difference.
Results

Figs 1, 2, and 3 show representative original record-
ings of systemic hemodynamics and regional myocardial dimensions during rest and during humoral and neuronal adrenergic activation without and with the addition of phentolamine from one dog of groups 1. 3, and 5, respectively.
Rest Versus Humoral and Neuronal
Adrenergic Activation
As compared with resting conditions, HR, maximum systolic LVP, mean AOP, maximum LV dP/dt, RMBF, and MVo02 rose substantially during humoral and neuronal adrenergic activation in all groups (Tables 2 through 6). As defined by the study protocol, there was no further change of HR and mean AOP (intra-aortic balloon) with the addition of phentolamine in any group.
Humoral Adrenergic Activation During Baseline Coronary Vasomotor Tone: Effect of a-Blockade (Group 1)
With the addition of phentolamine, transmural RMBF in the posterior wall increased by 23%. Compared with midmyocardial and subepicardial layers, the largest increase in RMBF occurred in subendocardial layers [1.42-±0.40 versus 1.90±t0.40 mL/(ming), P< .05] (Fig 4) . MVo02 also increased further with phentolamine.
There was, however, no further change in WYTMV of the posterior wall with phentolamine. RMBF and WTMV in the anterior control region did not change ( 
Humoral Adrenergic Activation During Maximal Coronary Vasodilation: Effect of a-Blockade (Group 2)
With the addition of phentolamine, transmural RMBF of the posterior region remained unchanged. Subendocardial blood flow increased further [4.99+±2.31 versus 5.53 + 2.56 mL/(min -g), P< .05], whereas subepicardial blood flow decreased [4.67+ 1.90 versus 3.93+ 1.66 mL/ (ming), P<.05] with phentolamine; midmyocardial blood flow did not change (Fig 5) . Neither MVo2 nor WTMV of the posterior wall were altered with phentolamine. RMBF and WTMV in the anterior control region did not change (Table 3) .
Humoral Adrenergic Activation Without Atropine and Atrial Pacing During Maximal Coronary Vasodilation: Effect of a-Blockade (Group 3)
In contrast to the observations in groups 1 and 2, humoral adrenergic activation without atropine and atrial pacing greatly increased end-diastolic LVP (Table  4 ). With the addition of phentolamine, no further changes in systemic hemodynamics occurred, and transmural RMBF of the posterior region remained unchanged. Subendocardial blood flow increased further [6.01±+1.41 versus 6.29±+1.27 mL/(min . g), P<.05], whereas subepicardial blood flow decreased [5.15+1.22 versus 4.66+1.38 mL/(min. g), P<.05] with phentolamine; midmyocardial blood flow did not change ( Fig  6) . Neither MVo2, WTMV, nor SLMV in the posterior wall were altered with phentolamine. RMBF and WTMV in the anterior control region did not change (Table 4 ).
Neuronal Adrenergic Activation During Baseline Coronary Vasomotor Tone: Effect of a-Blockade (Group 4)
Neuronal adrenergic activation induced a profound decrease in RMBF to all layers ( Table 5 ). With the addition of phentolamine, transmural RMBF in the posterior wall increased by 30%. The increase in RMBF was comparable in subendocardial, midmyocardial, and subepicardial layers (Fig 7) . Neither MVo2, WTMV, nor SLMV in the posterior wall changed further with phentolamine. Some increase in RMBF was also observed in the anterior myocardium, indicating recirculation of phentolamine. Wall function in the anterior control region, however, did not change ( Table 5 ).
Neuronal Adrenergic Activation During Maximal
Coronary Vasodilation: Effect of a-Blockade (Group 5) As perfusion pressure was increased, RMBF increased in all myocardial layers during cardiac sympathetic nerve stimulation (Table 6 ). With the addition of phentolamine, transmural RMBF of the posterior region remained unchanged. Subendocardial [6.10+±0.99 versus 5.91 + 1.11 mL/(min * g), P=NS] and midmyocar- (Table 6 ). 
Discussion
Major Findings
The major findings of this study are as follows: (1) During baseline coronary vasomotor tone, a-adrenergic coronary vasoconstriction induced by both humoral and neuronal adrenergic activation limits blood flow to all myocardial layers, preferentially to the subendocardium. 
Methodological Considerations
When subtle changes in transmural blood flow and its distribution are studied, a paired experimental design is without substitute. A paired simultaneous design enables a paired comparison of myocardial perfusion in two left ventricular regions that have identical left ventricular preload, afterload, and driving pressure and are influenced equally by drugs and humoral substances.17 '38 However, such experimental design does not account for the heterogeneity of RMBF, regional wall stress and deformation, and local neuronal norepinephrine release within different regions of the left ventricle. Huang and Feigl'7 had to account for such a difference in transmural blood flow distribution between the LCX-and the LADperfused regions by calculating and extrapolating the difference of inner and outer blood flow ratios between these regions. In the present study, we therefore preferred a paired design with sequential measurements in the same myocardial region, one without and the other with the addition of phentolamine. By carefully matching systemic hemodynamic parameters and with unchanged regional myocardial dimensions between the two measurements, this design permits the comparison of blood flow data within the same region of interest, without the need for normalizing data for differences between the control region and the region of interest.
Although our findings are in apparent contrast to the conclusions of Huang and Feigl,17 certain methodological differences between the two studies must be considered. In the study by Huang and Feigl, it is unclear whether a-adrenoceptors were completely blocked. The a-antagonist phenoxybenzamine was used, which is more potent in blocking a1than a2-adrenoceptors. 20 Therefore, a2-adrenoceptors, which are predominantly responsible for a-adrenergic coronary vasoconstriction,679 might not have been completely blocked. Because only normalized blood flow data were presented, it remains unclear how absolute subendocardial blood flow in the a-adrenergically blocked region was changed. As shown by several laboratories,151619 an increase in the subendocardial to subepicardial blood flow ratio during a-adrenoceptor activation does not necessarily imply an improvement in absolute subendocardial blood flow. To distinguish the effects of presynaptic and postsynaptic a-adrenoceptor blockade during dynamic exercise, Huang and Feigl studied a subset of dogs under additional /3-adrenoceptor blockade. However, significant differences in blood flow ratios were then demonstrated only when the data were statistically extrapolated beyond the measured range of MVo2.17
In the present study, the competitive a-antagonist phentolamine was used, which has been shown to effectively block both a1and a2-adrenoceptors.39 The effectiveness of the a-adrenoceptor blockade with phentolamine was also demonstrated in the present study, because phentolamine reversed the increase in blood pressure caused by the intravenous infusion of the physiological a-adrenoceptor agonist norepinephrine despite being administered regionally through the coronary artery. To our best knowledge, there is no evidence for a vasodilator effect of phentolamine inde-Local norepinephrine release during cardiac sympathetic nerve stimulation presumably results in a higher concentration of norepinephrine at the receptor site when LVP and AOP levels are comparable to those under humoral adrenergic activation. Therefore, as became apparent from preliminary experiments, a higher dosage of 50 gg/(min . kg) phentolamine had to be used in the experimental subgroups with neuronal adrenergic activation, also resulting in some recirculation and increase in anterior RMBF.
We have previously demonstrated that, with sustained infusion of norepinephrine, al-and a2-adrenoceptor blockade did not result in an increased HR and LV dP/dt, whereas with exercise such augmentation of HR and LV dP/dt occurred after a-blockade. These data suggested that, unless norepinephrine is released from nerve terminals, ie, during dynamic exercise or cardiac sympathetic nerve stimulation, no augmentation of norepinephrine release from nerve terminals results from presynaptic al-or a2-adrenoceptor blockade. 22 Consequently, only the dogs with cardiac sympathetic nerve stimulation were ,B-adrenergically blocked in the present study. Of course then, ,B-adrenoceptor-mediated effects of norepinephrine on the myocardium and the coronary vasculature are operative during humoral, but not during neuronal, adrenergic activation. Such persistent 83-adrenoceptor activation during humoral adrenergic activation is obvious from the systemic hemodynamic data, in particular dP/dt (Tables 2 through  4 ). Nevertheless, the conclusions of the present study are based on the removal of a-adrenergic effects by phentolamine at matched systemic hemodynamics and regional dimensions regardless of the degree of ,B-adrenoceptor activation, and phentolamine per se appears not to alter the extent of /8-adrenoceptor activation during humoral adrenergic activation. 22 Intense cardiac sympathetic nerve stimulation may impair the response to a subsequent cardiac sympathetic nerve stimulation. 40 Within the framework of the present study, the reproducibility of two series of cardiac sympathetic nerve stimulation 20 minutes apart was confirmed in a subset of experiments (Table 1) .
Both an increase in HR and an increase in end-diastolic LVP contribute to enhanced extravascular compression during adrenergic activation. In the present study, it was necessary to analyze the interaction between a-adrenergic coronary vasoconstriction and increased HR or end-diastolic LVP separately, because atropine and atrial pacing prevented any increase in end-diastolic LVP in group 2.
MVo2 was measured to detect metabolic changes associated with humoral and neuronal adrenergic activation. The increase in MVo2 after a-adrenoceptor blockade in group 1 probably represents an artifact and can be attributed to a mixture of coronary venous blood from the anterior control region with unchanged blood flow and oxygen extraction and the phentolaminetreated posterior region with increased blood flow and decreased oxygen extraction, since blood samples were taken unselectively from the coronary sinus. Such a mixture of coronary venous blood may be responsible for the calculated increase in MVo2 of the posterior region. This explanation is supported by the lack of a simultaneous increase in regional function and the fact that, with maximal coronary vasodilation in groups 2, 3, pendent of its a-adrenoceptor blocking action.
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Humoral Adrenergic Activation: Effect of a-Blockade
The hypothesis that a-adrenergic coronary vasoconstriction exerts a beneficial effect on transmural blood flow distribution under conditions of intense adrenergic activation is very attractive.1315-17 This hypothesis provides a rationale for the existence of a significant vasoconstrictor mechanism in a circulation in which vasoconstriction is otherwise inappropriate in situations of enhanced oxygen demand.
The results of the present study obtained during humoral adrenergic activation, however, lend no support for the existence of such a physiological function of a-adrenergic coronary vasoconstriction. Humoral rather than neuronal catecholamines exert significant a-adrenergic coronary constrictor tone during exercise. 18 On the basis of the hypothesis forwarded, one would predict that a-adrenergic blockade during intense humoral adrenergic activation would produce a vasodilation in the outer wall of the left ventricle associated with an increase in subepicardial blood flow. Consequently, at an unchanged transmural blood flow, there would be a concomitant decrease in blood flow to the inner layers. In the first protocol used (group 1), administration of phentolamine during humoral adrenergic activation increased blood flow across the entire left ventricular wall. Of note, however, is that the increase in blood flow was quantitatively largest in the subendocardium. This is in direct contrast to the results predicted by the stated hypothesis.
It may be argued that, since blood flow could be further increased transmurally in this experimental setting, the intensity of the humoral adrenergic activation was insufficient to increase blood flow to the extent at which the hypothesized flow limitation in the inner left ventricular wall caused by reduced diastolic perfusion time and the greatly enhanced extravascular compression were present. Indeed, since total posterior transmural blood flow was increased after the administration of phentolamine, no flow limitation was evident. Thus, the failure to observe a beneficial effect of a-adrenergic coronary vasoconstriction on transmural blood flow distribution may have reflected an inadequate level of adrenergic activation and blood flow increase.
In an effort to better mimic the setting of flow limitation during intense humoral adrenergic activation, two additional series of studies were performed (groups 2 and 3). The goal of these protocols was to determine the effect of a-adrenoceptor blockade in a setting of both intense humoral adrenergic activation and coronary blood flow limitation using dipyridamole. The presence of a coronary blood flow limitation was confirmed by the suppression of a reactive hyperemia response and the absence of an increase in transmural blood flow following the administration of phentolamine. The observed lack of an increase in transmural blood flow after phentolamine thus does not indicate lack of a-adrenergic vasoconstriction but confirms the situation of flow limitation. Of importance, therefore, is that, in the absence of changes in systemic hemodynamics and regional dimensions, a significant redistribution of blood flow occurred in the flow-limited perfusion bed icant increase in subendocardial and a significant decrease in subepicardial blood flow. Such redistribution of blood flow toward the subendocardium was observed in groups 2 and 3. Since an electromagnetic flow probe was implanted on the LCX in dogs of group 2, but not in those of group 3, the observed blood flow redistribution cannot be attributed to acute denervation resulting from the implantation of the flow probe on the LCX.
The dipyridamole-induced maximal coronary vasodilation somewhat differed among groups 2, 3, and 5.
Apart from substantial interindividual differences and potential differences in the coronary reserve of dogs of different age and breed, the somewhat lower maximum blood flow in group 2 ( Table 3 ) as compared with groups 3 ( Table 4 ) and 5 ( Table 6 ) probably reflects the difference in systemic hemodynamics, in particular, the higher HR in group 2.
With dipyridamole, the site of flow limitation is apparently proximal to the site of the phentolamineinduced flow redistribution between inner and outer layers. A redistribution of coronary resistance from coronary microvessels toward more upstream arterial vessels with dipyridamole has been demonstrated previously. 41 The present study, however, can only speculate on the segmental site of coronary vasomotor changes.
Previous studies using intracoronary infusion of a-adrenoceptor agonists15'19742 rather than an a-adrenoceptor antagonist, as in the present study, did also not observe a transmural blood flow redistribution favoring the subendocardium during a-adrenoceptor activation. Whereas these previous studies using a-adrenoceptor agonists found transmurally uniform coronary constrictor responses, the improvement in blood flow following a-adrenoceptor blockade in the present study was most pronounced in the subendocardium. The mechanism of this preferential increase in subendocardial blood flow following a-adrenoceptor blockade remains unclear. Of interest, however, is the fact that during myocardial ischemia (ie, a flow limitation below the autoregulatory range as opposed to the flow limitation beyond the autoregulatory range used in the present study), a-adrenoceptor blockade also preferentially improved subendocardial blood flow. 43, 44 Neuronal Adrenergic Activation: Effect of a-Blockade Without baseline coronary vasomotor tone, the effect of neuronal a-adrenergic coronary vasoconstriction on the transmural blood flow distribution was not different from that of humoral a-adrenergic coronary vasoconstriction, as phentolamine improved blood flow to all layers (Table 5 ). However, with maximal coronary vasodilation by dipyridamole, neuronal, in contrast to humoral, a-adrenergic coronary vasoconstriction had a beneficial effect on the transmural blood flow distribution. a-Adrenergic blockade with phentolamine therefore increased blood flow to outer layers at the expense of inner layers. A beneficial effect of neuronal, but not humoral, a-adrenergic coronary vasoconstriction on the transmural blood flow distribution was previously observed.15 6 The reasons for such transmurally nonuniform blood flow response to neuronal norepinephrine are not completely clear. A transmural gradient of sympathetic innervation and resulting transmitter reafter the administration of phentolamine, with a signiflease appears unlikely, since the decrease in blood flow during cardiac sympathetic nerve stimulation with baseline coronary vasomotor tone is transmurally uniform ( Table 5 ). A preferential inhibition of sympathetic neurotransmission by the enhanced levels of adeno-sine45 in inner myocardial layers appears possible,15 but there are currently no data to support this idea. MVo2 and Regional Myocardial Function During Humoral and Neuronal Adrenergic Activation: Effect of a-Blockade Apart from the increase in calculated MVo2 in group 1, which most likely reflects an artifact (see above), neither MVo2 nor regional myocardial function was changed in any group with a-adrenergic blockade by phentolamine. Our study, however, was not designed to test the previously reported beneficial effect of improved blood flow after a-adrenoceptor blockade through a Gregg phenomenon or removal of a flow limitation for contractile function.2627 With baseline coronary vasomotor tone, there is probably sufficient metabolic regulation to prevent an impact of a-adrenergic coronary constriction on contractile function, whereas during maximal coronary vasodilation there is luxury perfusion, and function and MVo2 are uncoupled from blood flow.
Conclusion
In conclusion, there is no evidence for a beneficial effect of a-adrenergic coronary vasoconstriction on transmural blood flow distribution during humoral adrenergic activation and during neuronal adrenergic activation at baseline coronary vasomotor tone. During neuronal adrenergic activation in the presence of maximal coronary vasodilation, however, a-adrenoceptor blockade with phentolamine redistributes blood flow toward subepicardial layers at the expense of subendocardial layers. Thus, during neuronal adrenergic activation, a-adrenergic coronary vasoconstriction may exert a beneficial effect on transmural myocardial blood flow distribution.
The impact of a-adrenergic coronary vasoconstriction on transmural blood flow distribution in our studies was rather small, and the question of whether a-adrenergic coronary vasoconstriction serves any physiological purpose remains. In this respect, it was proposed that a-adrenergic coronary vasoconstriction of small coronary arteries and large arterioles protects the metabolically dilated microcirculation from increased filtration pressure during intense adrenergic activation (W.M. Chilian, personal communication). This hypothesis remains to be adequately tested. In contrast, a-adrenergic coronary vasoconstriction may serve no physiological purpose at all. This idea cannot be experimentally tested but could only be supported by the minor extent of vasoconstriction in the coronary circulation as compared with other vascular beds. 46 
